Morphogenesis, Inc.   Report issue

For profit Phase 1
Founded: Tampa FL United States (1995)

Organization Overview

First Clinical Trial
2018
NCT03655756
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Morphogenesis, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

ifx-hu2.0 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Merkel Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Melanoma (Phase 1)

Skin Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 1